Buy Azilsartan and Chlorthalidone

Azilsartan and Chlorthalidone

Azilsartan and Chlorthalidone: Combination Medication Overview

• Active ingredients: Azilsartan medoxomil, chlorthalidone
• Therapeutic class: Heart & Blood Pressure (angiotensin II receptor blocker + thiazide-like diuretic)
• Formulation: Oral pill, 40 mg/12.5 mg per tablet
• Regulatory status in Hong Kong: Prescription-only medicine, approved by the Pharmacy and Poisons Board

This article provides an evidence-based, patient-focused overview of the azilsartan + chlorthalidone combination. Information is intended for adults and does not replace professional medical advice.

How Azilsartan and Chlorthalidone Work in the Body

• Azilsartan medoxomil is a prodrug that is rapidly converted to azilsartan, an angiotensin II type 1 (AT₁) receptor blocker. By preventing angiotensin II from binding to its receptor, azilsartan relaxes arterial smooth muscle, leading to vasodilation and reduced systemic vascular resistance.
• Chlorthalidone is a thiazide-like diuretic that inhibits sodium-chloride reabsorption in the distal convoluted tubule. This promotes natriuresis and modest water loss, lowering plasma volume and decreasing cardiac preload.
• The combination yields a dual antihypertensive effect: azilsartan reduces afterload, while chlorthalidone reduces preload. Onset of blood-pressure lowering typically occurs within a few hours, with peak effect reached in 1-2 weeks and a duration of action lasting 24 hours, supporting once-daily dosing.

Conditions Treated with Azilsartan and Chlorthalidone

• Essential (primary) hypertension - the medication is indicated for adults whose blood pressure remains insufficiently controlled with monotherapy or who require combination therapy for more rapid control.
• In Hong Kong, the product is approved for the treatment of high blood pressure as defined by the local clinical guidelines (systolic ≥ 140 mm Hg or diastolic ≥ 90 mm Hg).

Patient Suitability and Contraindications

Who Should Use This Medication?

• Adults diagnosed with essential hypertension who need an ACE-inhibitor/ARB-plus-diuretic regimen.
• Patients who can tolerate a thiazide-like diuretic and have no history of severe renal artery stenosis.

Absolute Contraindications

• Known hypersensitivity to azilsartan, chlorthalidone, or any component of the tablet.
• Pregnancy (particularly the second and third trimesters) - ARBs are contraindicated because of risk to the fetus.
• Severe renal impairment (eGFR < 30 mL/min/1.73 m²) or anuria.
• Hyperkalemia (serum potassium > 5.5 mmol/L) at baseline.

Relative Contraindications

• Moderate renal impairment (eGFR 30-59 mL/min/1.73 m²) - dose may need adjustment and close monitoring of electrolytes.
• Hepatic impairment - azilsartan is metabolized hepatically; caution is advised.
• History of gout, as chlorthalidone can increase serum uric acid.
• Type 2 diabetes mellitus with poor glycaemic control, because thiazide-like diuretics may raise blood glucose.

Special Populations

• Pregnancy & lactation: Not recommended; alternative antihypertensives should be used.
• Elderly: Start at the recommended dose; monitor for orthostatic hypotension and electrolyte disturbances.
• Patients with low potassium or sodium: May require potassium-sparing adjuncts or dietary adjustments.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Dizziness or light-headedness, especially after the first dose.
• Headache.
• Fatigue.
• Increased urination (diuretic effect).
• Mild gastrointestinal upset (nausea, abdominal discomfort).

These effects are usually transient and improve with continued therapy or dose adjustment.

Serious Adverse Events

• Severe hypotension - marked drop in blood pressure causing fainting, syncope, or shock; seek emergency care.
• Electrolyte abnormalities - hypokalemia, hyponatremia, or hyperuricemia; routine labs are recommended.
• Acute kidney injury - rising serum creatinine (>30 % from baseline) after initiation; discontinue and evaluate renal function.
• Angio-edema - rare but potentially life-threatening swelling of the face, lips, tongue, or airway; requires immediate medical attention.

Drug Interactions

• Potassium-sparing agents (e.g., spironolactone, amiloride) - may raise serum potassium when combined with azilsartan; monitor potassium levels.
• Other antihypertensives (beta-blockers, calcium-channel blockers) - additive blood-pressure lowering; dose titration may be needed.
• Non-steroidal anti-inflammatory drugs (NSAIDs) - can blunt the antihypertensive effect and increase risk of renal dysfunction.
• Lithium - chlorthalidone can reduce lithium clearance, raising the risk of lithium toxicity; adjust lithium dose accordingly.
• Cytochrome P450 2C9 substrates (e.g., warfarin, certain oral hypoglycemics) - chlorthalidone may modestly affect metabolism; monitor therapeutic levels.

Food and Lifestyle Interactions

• Salt intake: High dietary sodium can diminish the diuretic’s effect; a low-sodium diet is advisable.
• Alcohol: Moderate consumption is permissible, but excessive intake may exacerbate hypotension.
• Driving or operating machinery: Dizziness may occur, especially after initiating therapy; avoid hazardous activities until you know how the medication affects you.
• Grapefruit juice: No clinically significant interaction with azilsartan, but avoid excessive consumption of other fruit extracts that may affect blood pressure.

Dosing and Administration Guidelines

• Standard dose: One tablet containing 40 mg azilsartan medoxomil and 12.5 mg chlorthalidone taken orally once daily.
• Timing: Preferably in the morning with or without food; taking the medication at the same time each day promotes steady blood-pressure control.
• Missed dose: If you remember within 12 hours, take the missed tablet. Otherwise, skip it and resume the regular schedule. Do not double-dose.
• Renal or hepatic impairment: No dose reduction is formally recommended for the 40/12.5 mg tablet, but clinicians may choose to monitor renal function and electrolytes more frequently and adjust therapy if needed.
• Overdose: Symptoms may include marked hypotension, rapid heart rate, electrolyte imbalance, and renal dysfunction. Seek emergency medical care; supportive measures and electrolyte correction are the mainstays of treatment.
• Discontinuation: The medication can be stopped abruptly under physician guidance; however, gradual tapering may be considered in patients with well-controlled blood pressure to avoid rebound hypertension.

Monitoring and Follow-Up

• Baseline labs: Serum creatinine, eGFR, electrolytes (especially potassium and sodium), and uric acid.
• Follow-up labs: At 1-2 weeks after initiation, then monthly for the first 3 months, and periodically thereafter, or as clinically indicated.
• Blood-pressure checks: Home monitoring or clinic visits every 1-2 weeks until target pressure is reached, then every 3-6 months.
• Signs to report: Persistent dizziness, swelling, severe muscle cramps, dark urine, or sudden rise in blood pressure.

Storage and Handling

• Store the tablets at room temperature (20-25 °C) away from moisture, heat, and direct sunlight.
• Keep the container tightly closed and out of reach of children.
• Do not use the medication after the expiration date printed on the package.
• Dispose of unused tablets according to local pharmacy guidelines or take-back programs.

Medication-Specific Glossary

Angiotensin II Receptor Blocker (ARB)

A class of drugs that inhibit the binding of angiotensin II to AT₁ receptors, leading to vasodilation and lowered blood pressure.

Thiazide-like Diuretic

A diuretic that acts on the distal convoluted tubule to promote sodium and water excretion; chlorthalidone is more potent and longer-acting than classic thiazides.

Electrolyte Imbalance

Disturbances in the levels of minerals such as potassium, sodium, or uric acid that can affect heart rhythm, muscle function, and overall health.

Medical Disclaimer

This article provides educational information about azilsartan and chlorthalidone and is not a substitute for professional medical advice. Treatment decisions, including the use of unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.